|
|
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Vardenafil}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
|
| |
|
| '''''For patient information, click <u>[[Vardenafil tablet (patient information)|here]]'''''</u>.
| |
|
| |
| ==Overview==
| |
|
| |
| ==Category==
| |
|
| |
| ==US Brand Names==
| |
|
| |
| ==FDA Package Insert==
| |
|
| |
| ''' [[Vardenafil tablet indications and usage|Indications and Usage]]'''
| |
| '''| [[Vardenafil tablet dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Vardenafil tablet dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Vardenafil tablet contraindications|Contraindications]]'''
| |
| '''| [[Vardenafil tablet warnings|Warnings and Precautions]]'''
| |
| '''| [[Vardenafil tablet adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Vardenafil tablet drug interactions|Drug Interactions]]'''
| |
| '''| [[Vardenafil tablet use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Vardenafil tablet overdosage|Overdosage]]'''
| |
| '''| [[Vardenafil tablet description|Description]]'''
| |
| '''| [[Vardenafil tablet clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Vardenafil tablet nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Vardenafil tablet clinical studies|Clinical Studies]]'''
| |
| '''| [[Vardenafil tablet how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Vardenafil tablet patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Vardenafil tablet labels and packages|Labels and Packages]]'''
| |
|
| |
| ==Mechanism of Action==
| |
|
| |
| ==References==
| |
|
| |
| {{Reflist|2}}
| |
|
| |
| [[Category:Drugs]]
| |
| ==[[Vardenafil (patient information)|For patient information, click here]]==
| |
| ==Overview==
| |
| '''Vardenafil''' ([[International Nonproprietary Name|INN]]) is a [[PDE5 inhibitor]] used in the treatment of [[erectile dysfunction]]. It can assist men with this disorder in achieving and maintaining an [[erection]] during [[sexual activity]]. It is commonly marketed under the trade name '''Levitra''' ([[Bayer AG]]).
| |
|
| |
| ==History==
| |
| Vardenafil was co-marketed by [[Bayer|Bayer Pharmaceuticals]] and [[GlaxoSmithKline|GSK]] under the trade name ''Levitra''. As of 2005, the co-promotion rights of [[GlaxoSmithKline|GSK]] on ''Levitra'' have been "transferred back" to Bayer in many markets outside of the United States. In Italy, Bayer markets the product as ''Levitra'' and GSK markets the product as '''Vivanza'''. Due to European Union trade rules, parallel imports may result in the ''Vivanza'' branded packs being seen alongside ''Levitra'' packs in pharmacies in other EU member states.
| |
|
| |
| ==Clinical use==
| |
| {{main|PDE5 inhibitor}}
| |
|
| |
| Indications and contraindications are as for other [[PDE5]] inhibitors. As a PDE5 inhibitor, vardenafil is closely related in both function and marketing to [[sildenafil]] (Viagra) and [[tadalafil]] (Cialis). Structurally, the vardenafil molecule differs from sildenafil by only a [[methyl group]] and the position of one [[nitrogen]] atom in its structure. It has a relatively short effective time, comparable to sildenafil.
| |
|
| |
| ===Adverse drug reactions===
| |
| More common adverse drug reactions (ADRs) are as per other [[PDE5 inhibitor]]s and are listed on that page.
| |
|
| |
| Common vardenafil-specific ADRs include: nausea. Infrequent ADRs include: abdominal pain, back pain, [[photosensitivity]], abnormal vision, eye pain, facial [[oedema]], [[hypertension]], palpitation, [[tachycardia]], [[arthralgia]], [[myalgia]], rash, itch, [[priapism]]. (Rossi, 2004)
| |
|
| |
| The use of products containing vardenafil has also been associated with serious side-effects which include serious cardiac events such as heart attacks. In rare cases, the use of vardenafil may result in penile tissue damage and permanent loss of potency.
| |
| Health Canada (2006)
| |
|
| |
| On October 18, 2007, the [[FDA]] announced that a warning about possible [[Deafness|sudden hearing loss]] would be added to the drug labels of vardenafil and other PDE5 inhibitors.<ref name="FDA PDE5">{{cite web | url= http://www.fda.gov/bbs/topics/NEWS/2007/NEW01730.html| title= FDA Announces Revisions to Labels for Cialis, Levitra and Viagra| author= | publisher= [[Food and Drug Administration]] }}</ref>
| |
|
| |
| ===Drug interactions===
| |
| Products containing vardenafil should not be used by individuals who are taking any nitrate medication because combining these products could result in the development of potentially life-threatening low blood pressure.
| |
|
| |
| ===Dose forms===
| |
| It is available in 2.5 mg, 5 mg, 10 mg, and 20 mg doses in round orange tablets. The normal starting dose is 10 mg (roughly equivalent to 50 mg of [[sildenafil]]). Vardenafil should be taken 25–60 minutes prior to sexual activity, with a maximum dose frequency of once per day.
| |
| In some territories, such as the UK, only certain doses may be available, i.e. 5 mg, 10 mg, and 20 mg.
| |
|
| |
| == See also ==
| |
| * [[PDE5 inhibitor]]
| |
| * [[Sildenafil]] (Viagra)
| |
| * [[Tadalafil]] (Cialis)
| |
|
| |
| ==Notes==
| |
| {{reflist|2}}
| |
|
| |
| == External links ==
| |
| *[http://www.levitra.com/ Official Levitra website]
| |
| *[http://www.fda.gov/cder/consumerinfo/druginfo/levitra.htm FDA's Consumer Information]
| |
| *[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=110634 PubChem Information]
| |
|
| |
| {{Urologicals}}
| |
| {{Phosphodiesterase inhibitors}}
| |
|
| |
|
| |
| [[Category:PDE5 inhibitors]]
| |
| [[Category:Drugs]]
| |
|
| |
| [[bg:Варденафил]]
| |
| [[da:Vardenafil]]
| |
| [[de:Vardenafil]]
| |
| [[fr:Vardénafil]]
| |
| [[hu:Vardenafil]]
| |
| [[pt:Vardenafila]]
| |
| [[ru:Варденафил]]
| |
| [[fi:Vardenafiili]]
| |
| [[uk:Варденафіл]]
| |
|
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |